Notice for trastuzumab emtansine (Roche Products Pty Limited)
Active ingredients
trastuzumab emtansine
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
Trastuzumab emtansine, as a single agent, is indicated for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual disease after pre-operative systemic treatment that included HER2-targeted therapy.